ClinicalTrials.gg
RecruitingNCT07106918Updated Nov 25, 2025

A Clinical Trial of SIBP-A16 Injection in Healthy Adults

An Early Phase 1 interventional study of SIBP-A16 injection and Nirsevimab in Respiratory Syncytial Virus (RSV), sponsored by Shanghai Institute Of Biological Products. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Shanghai Institute Of Biological Products (part of Sinopharm) · Early Phase 1, Interventional, and Prevention

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is a randomized, double-blind, placebo/positive control Phase Ia clinical trial evaluating the safety, tolerability, and pharmacokinetics of SIBP-A16 injection in healthy adults

Read the detailed description

This study plans to set up 5 queues, with queues 1, 3, 4, and 5 each containing 20 participants in the experimental group and 4 participants in the placebo group. Queue 2 contains 20 participants in the experimental group, 20 participants in the positive control group, and 4 participants in the placebo group. The total number of participants included in the five queues is 140. SIBP-A16 injection and placebo will be administered in four different doses and two different ways of administration. The study adopted a sequential injection design. After completing a 14-day preliminary safety observation of drug administration in the previous group, the Safety Review Committee (SRC) will conduct a preliminary safety assessment. Once the SRC evaluation results are safe (not meeting the dose escalation termination criteria), the next group will be enrolled.

02

Conditions studied

  • Respiratory Syncytial Virus (RSV)

Keywords

  • Respiratory syncytial virus
  • SIBP-A16
  • safety
  • tolerability
  • pharmacokinetics
03

In context

Lead sponsor

Shanghai Institute Of Biological Products is the lead sponsor of 34 studies on the registry; 14 are open to participants now.

First submitted after Shanghai Institute Of Biological Products became part of Sinopharm.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy individuals aged 18 to 45 on the day of enrollment, regardless of gender.
  • Male body weight ≥ 50.0 kg, female body weight ≥ 45.0 kg, between 19.0 and 27.0 kg/m2 (including critical values).
  • Screening period physical examination, vital sign examination, 12 lead , chest X-ray or clinical laboratory examination, and other auxiliary examination results show normal or abnormal without clinical significance as judged by the researcher.
  • Individuals who voluntarily participate in clinical trials and sign forms.
  • Individuals are able to communicate well with the researchers and understand and comply with the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  • Known to have a history of serious clinical diseases such as mental system, circulatory system, endocrine system, digestive system, respiratory system, hematological and metabolic abnormalities, or any other diseases that can interfere with the test results.
  • Individuals with a history of drug allergies or specific allergies, or individuals with allergies, or those known to be allergic to the components or analogues of this drug.
  • During the screening period, individuals with abnormal results from physical examination, laboratory tests and clinical significance were identified by the researchers as having an impact on the evaluation of this trial.
  • During the screening period, male individuals with ≥ 450 milliseconds and female individuals with QTcF ≥ 470 milliseconds on .
  • Individuals who have received monoclonal/polyclonal antibody drugs within 6 months prior to screening.
  • Individuals have received immunoglobulin or blood product treatment within 6 months prior to screening.
  • Individuals who have received passive immune agents, , or within the 6 months prior to screening.
  • Individuals who experience acute illnesses such as fever ≥ 37.3 ℃ (armpit temperature) and diarrhea within one week before their first medication.
  • Individuals experienced symptoms and signs of acute upper respiratory tract infection within 2 weeks prior to the first use of medication.
  • Individuals who have received the respiratory syncytial virus (RSV) vaccine in the past.
  • Individuals have received any vaccine within 30 days prior to screening.
  • Select individuals who have smoked at least 5 cigarettes per day within the first 3 months and those who cannot quit smoking throughout the entire trial period.
  • Individuals with an average weekly alcohol consumption of ≥ 14 units within the first 3 months of screening, or those who cannot abstain from alcohol during the trial period.
  • Individuals have a history of long-term excessive consumption of tea, coffee, or caffeinated beverages.
  • Individuals have used any medication or health supplement within the 14 days prior to screening.
  • Individuals with a history of drug abuse/dependence or drug use within the past year prior to screening.
  • Screening individuals who have participated in any drug clinical trials and have used the drug within the previous 3 months.
  • Individuals with a history of blood donation or significant bleeding within the previous 4 weeks prior to screening, or those planning to donate blood or blood components during the study period.
  • Pregnant or lactating women.
  • Those who have plans to conceive, donate sperm or eggs, or are unable to voluntarily take effective measures during the trial period (including partners).
  • Those who have special dietary requirements and cannot follow a reasonable and normal diet.
  • The researchers believe that the individuals may have other situations that may affect compliance or be unsuitable to participate in this trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    SIBP-A16 injection

    Strength: dose 1, dose 2 dose 3 and dose 4. The participants enrolled will be randomly assigned to different dose groups, and they will be enrolled in groups according to the dose from low to high.

    Biological: SIBP-A16 injection

  • Active comparator
    Nirsevimab

    Participants injected Nirsevimab will compare with participants in dose 2 experimental group.

    Biological: Nirsevimab

  • Placebo comparator
    SIBP-A16 buffer solution

    Participants in the placebo group from different queues will receive the same dose as the corresponding experimental group

    Other: SIBP-A16 buffer solution

Interventions

  • BiologicalSIBP-A16 injection

    Single administration via intramuscular or intravenous injection. All participants received a single injection of the corresponding dose.

  • BiologicalNirsevimab

    Single administration via intramuscular.

  • OtherSIBP-A16 buffer solution

    Single administration via intramuscular or intravenous injection. All participants received a single injection of the corresponding dose.

06

What researchers measure

Primary outcomes

  1. AE (Adverse Events)

    That is adverse events, any adverse events that occurred to the participant during the study period.

    Time frame: From day 1 to day 361 after administration

  2. SAE (Serious Adverse Events)

    That is serious adverse events, any serious adverse events that occurred to the participant during the study period.

    Time frame: From day 1 to day 361 after administration

  3. Adverse Event of Special Interest (AESI)

    Adverse events defined in the protocol that require special attention, such as abnormal liver function, etc.

    Time frame: From day 1 to day 361 after administration

Secondary outcomes

  1. AUC (Area Under The Plasma Concentration Versus Time Curve)

    It shows the degree to which a drug is absorbed and used in the body.

    Time frame: Based on multiple pharmacokinetic blood collection points specified in the protocol

  2. Cmax (Peak Plasma Concentration)

    It shows the highest plasma concentration of a drug that can be achieved after administration.

    Time frame: Based on multiple pharmacokinetic blood collection points specified in the protocol

  3. Tmax (Peak Time)

    That is peak time of drug action, it shows the time required to reach the maximum concentration on the participant plasma concentration curve after administration.

    Time frame: Based on multiple pharmacokinetic blood collection points specified in the protocol

Other outcomes

  1. Level of Anti-drug antibody (ADA)

    If ADA is positive, further check the levels of neutralizing antibodies against SIBP-A16 or neutralizing antibodies against Nisevere monoclonal antibody

    Time frame: Before injection, on the 15th, 31st, 91st, 151st, 271st, and 361st days after administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Apr 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 6, 2025
StartActual
Aug 17, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07106918
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Aug 17, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Nov 25, 2025

Study contacts

Dan dan Chen, Master
Contact
ddchen.sh@sinopharm.com
+862162800991
Bin Wu, Bachelor
Contact
wubin50@sinopharm.com
+862162800991
Chao lin Huang
principal investigator · Wuhan Jinyintan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion